CardioComm Solutions, Inc
CardioComm Press Releases
 
  Previous Page previous page
About CardioComm
 

Letter from the CEO, August 28, 2012:
Invitations for HeartCheckTM PEN Device & Smart Monitoring Product Evaluation Starts this Week

We have launched the first phase of the HeartCheckTM and Smart Monitoring evaluation today.  We have now all required regulatory submissions that held our time table back by approximately one month and we thank you for your patience in waiting for this announcement. As of today, those who have gone through the pre-registration process (with valid email addresses) through our www.theheartcheck.com website have been contacted. 

As you are aware, Smart Monitoring is a new and innovative service that we believe fully addresses the needs of the public and will be tremendously useful to consumers and the medical field alike.  The service makes available to anyone the opportunity for self-monitoring for cardiac arrhythmias which could serve to reduce risk for developing heart disease or having a stroke. We also believe input and feedback from our users is an important step in finalizing a product’s roll-out. We are now immediately in advance of our planned launch and will use the feedback of selected participants in refining and enhancing subsequent releases of our hardware and software offerings.

Those who receive the invitation letter will be asked to respond via email to heartchecktest@theheartcheck.com by Wednesday, September 5, 2012. Once a confirmation of intent to participate is received, they will then be asked to follow a few steps.

  1. Complete a Non-Disclosure Agreement (NDA), to ensure that no information associated with this evaluation is shared before CardioComm Solutions announces the results, especially since the product and service are not currently publically available for purchase and use.
  2. Complete a short medical survey to understand the participant’s general medical history. The information from the survey will remain confidential and will help evaluate the HeartCheckTM Smart Monitoring system more accurately.
  3. Up to 70 people who sign and return the NDA and provide the completed questionnaire will be selected to participate.  Those individuals will be sent a credit card payment confirmation form for the purchase of one HeartCheckTM PEN device for one hundred US dollars ($100 US).
  4. Instructions will be provided to each participant once the HeartCheckTM PEN has been shipped. These will include how to download GEMSTM Home and how to use the HeartCheckTM PEN and Smart Monitoring service. Specifically, participants will be shown how to do a first heart rhythm recording and upload it so as to have a first ECG reading, an ECG report provided and then the option to unlock the HeartCheckTM PEN to enable ECG viewing in subsequent recordings.

During the evaluation period we will accept one ECG per day per participant.  The daily ECG will be reviewed and at the end of the product evaluation a summary report will be provided for each participant. If during the evaluation phase we disclose an arrhythmia that is not typical, such as atrial fibrillation, we will send an ECG report to the participant that generated that ECG recording.

The reading and reporting of a heart rhythm will take 24 hours. Users should go to the emergency room of the hospital immediately or call their doctor if they are concerned about their symptoms or feel unwell.

This is an exciting time at CardioComm Solutions as we continue to develop and roll-out new and innovative products and services.

Again, thank-you for your interest and support of CardioComm Solutions.

Very kind regards,

Etienne Grima, CEO
CardioComm Solutions, Inc.





Forward-looking statements
This release may contain certain forward-looking statements with respect to the financial condition, results of operations and business of CardioComm Solutions and certain of the plans and objectives of CardioComm Solutions with respect to these items. By their nature, forward-looking statements involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these forward-looking statements.







Investor Information

 

July 31, 2012
We are pleased to provide a preview of the new HeartCheck PEN product brochure that is now available on our website


June 27 2012
About WAISCO Inc from Medical
Coaches Incorporated


June 20 2012
"It’s been a busy two months for CardioComm Solutions, Inc."

April 30 2012
"CardioComm receives excellent initial response from Hospimedica International Advertising Campaign"

April 27 2012
CardioComm attends the World Congress of Cardiology Scientific Sessions in Dubai

May 8 2012
CardioComm Solutions Schedules Annual General Meeting (AGM) for June 27th, 2012


Investor Information


Etienne Grima
- MSc CHE
Chief Executive Officer

Anatoly Langer
MD, M.Sc, FRCPC, FACC
Chairman of the Board

William E. Smith
Board Member

Yury Levin

Board Member

David Newman
Board Member

Simi Grosman - MBA

Consultant & Board Member

Investor Information


Etienne Grima - MSc CHE
Chief Executive Officer

Wendy Hsieh
Chief Financial Officer

Wade Barnes
Chief Technology Officer

Mona Palfreyman

Director of Customer Support & Quality Assurance

View more

 

Arrhythmia EKG Management | 12 Lead ECG Management | ECG Software | EKG Management | Web Based ECG | EKG Software